Structures by: Urbina J. F.
Total: 28
Bis(3-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4
(C16H15N3O)2(AgBF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.666(2)Å b=12.237(2)Å c=13.013(2)Å
α=109.136(13)° β=114.266(8)° γ=92.310(14)°
Bis(4-((6,7-dimethylbenzimidazol-1-yl)methyl)benzamide), AgBF4
(C17H17N3O)2Ag(BF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.9140(7)Å b=8.4229(6)Å c=19.7055(13)Å
α=90.00° β=102.108(3)° γ=90.00°
(4-((5,6-dimethylbenzimidazol-1-yl)methyl)benzamide)2, AgAsF6
(C17H17N3O)2AgAsF6
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.1269(6)Å b=9.2459(5)Å c=10.0615(7)Å
α=97.921(4)° β=89.950(4)° γ=98.904(4)°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (AsF6)
(C16H15N3O)2Ag(AsF6)(CH4O)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.3084(4)Å b=18.5828(11)Å c=25.1620(15)Å
α=90.00° β=96.8060(10)° γ=90.00°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
(C16H15N3O)2Ag(SbF6)(O)3
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.5069(5)Å b=18.6924(12)Å c=24.9808(17)Å
α=90.00° β=98.4920(10)° γ=90.00°
Bis(2-methyl-3-((benzamide-3-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
(C16H15N3O)2Ag(SbF6)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.2644(4)Å b=13.2045(6)Å c=14.2022(6)Å
α=74.5580(10)° β=81.7510(10)° γ=72.2750(10)°
Bis(4-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4, H2O
(C16H15N3O)2(AgBF4)(O)3.4
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=40.141(3)Å b=4.9633(5)Å c=18.6857(19)Å
α=90.00° β=96.855(6)° γ=90.00°
3-((2-methylbenzimidazol-1-yl)methyl)benzamide, Ag (AsF6)
(C16H15N3O)2Ag(AsF6)(CH4O)0.5
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.8443(8)Å b=12.1157(7)Å c=13.3329(8)Å
α=66.333(3)° β=69.670(3)° γ=87.960(3)°
1-(3-pyridylmethyl)benzimidazole, 3,5-diNO2PhCOOH, 3- Me2NPhCOOH
(C13H11N3)(C7H4N2O6)(C9H11NO2)
Chemical Communications (2005)
a=8.1324(7)Å b=10.8110(9)Å c=15.3761(13)Å
α=95.489(4)° β=90.318(5)° γ=91.503(5)°
1-(3-pyridylmethyl)-2-methyl-BzIm, 3,5-diNO2PhCOOH, 4- NO2PhCOOH
(C14H13N3)(C7H4N2O6)(C7H5NO4)
Chemical Communications (2005)
a=7.7318(8)Å b=7.0062(7)Å c=49.395(5)Å
α=90.00° β=91.012(6)° γ=90.00°
N-((3-pyridyl)methyl)benzimidazole, 4-NO2-PhCOOH, 3,5-di(NO2)- PhCOOH
(C13H11N3)(C7H5NO4)(C7H4N2O6)
Chemical Communications (2005)
a=7.7602(11)Å b=15.269(2)Å c=22.456(3)Å
α=82.064(3)° β=81.610(3)° γ=78.915(3)°
(1,3-Ph2acac)Co(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)
Co(C15H11O2)2(C16H15N3O)2(C4H8O)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9670(6)Å b=11.2006(7)Å c=15.3238(9)Å
α=75.533(3)° β=80.377(4)° γ=79.221(4)°
(1,3-Ph2acac)Ni(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)2
Ni(C15H11O2)2(C16H15N3O)2(C4H8O)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9948(19)Å b=11.185(2)Å c=15.409(3)Å
α=75.737(9)° β=79.844(13)° γ=78.971(16)°
Cu{[4-(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide}2(F6-acac)2 (CH3CN)2
Cu(C17H17N3O)2(C5HO2F6)2(C2H3N)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.349(3)Å b=10.688(3)Å c=12.680(3)Å
α=98.217(6)° β=110.457(5)° γ=104.465(5)°
{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
(C11H11N3O)2(C5H1F6O2)4Cu2
Inorganic Chemistry (2009) 48, 4052-4061
a=9.7354(11)Å b=11.1497(12)Å c=23.870(3)Å
α=90.00° β=96.985(2)° γ=90.00°
Bis{4-[(pyrazol-1-yl)methyl]benzamide} (Ph2-acac)2 Ni(II) bis{ethanol} (Ph2-acac)2 Ni(II)
(C11H11N3O)2(C15H11O2)2Ni(C2H6O)2(C15H11O2)2Ni
Inorganic Chemistry (2009) 48, 4052-4061
a=9.0170(6)Å b=12.3493(8)Å c=17.6357(12)Å
α=86.3190(10)° β=78.0890(10)° γ=72.2410(10)°
{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
(C11H11N3O)2(C5H1F6O2)4Cu2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.0325(10)Å b=15.1765(15)Å c=16.6440(16)Å
α=90.00° β=99.957(2)° γ=90.00°
527 4-[(2-phenylimidazol-1-yl)methyl]benzamide, mu-Cu2(F-PhCOO)4
(C17H15N3O)2(C7H4O2F)4Cu2(C2H3N)5
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9536(9)Å b=11.2155(8)Å c=14.9765(12)Å
α=77.570(6)° β=78.159(4)° γ=74.526(5)°
BS-2-11e mu(o-FPhCOO)4 Cu2[4-imidazolylmethylbenzamide]2
(C11H11N3O)2Cu2(C7H4O2F)4
Inorganic Chemistry (2009) 48, 4052-4061
a=10.8218(9)Å b=19.4000(14)Å c=12.0541(8)Å
α=90.00° β=108.346(4)° γ=90.00°
BS-3-44-2A 4-[(pyrazol-1-yl)methyl]PhCONH2, mu4-(AcO)Cu CH3CN
(C11H11N3O)2Cu2(C2H3O2)4(C2H3N)2
Inorganic Chemistry (2009) 48, 4052-4061
a=7.5896(5)Å b=10.0990(7)Å c=13.3959(8)Å
α=68.531(4)° β=82.310(3)° γ=72.114(3)°
Mu(OAc)4 Cu2 {3-[(pyrazol-1-yl)methyl]benzamide}2
(C2H3O2)4Cu2(C11H11N3O1)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.0173(4)Å b=10.1615(5)Å c=11.4846(6)Å
α=110.1640(10)° β=109.1250(10)° γ=90.5040(10)°
4-[(2-methylbenzimidazol-1-yl)methyl]benzamide
C16H15N3O
Crystal Growth & Design (2005) 5, 3 1283
a=9.9852(13)Å b=15.912(2)Å c=8.3680(13)Å
α=90.00° β=93.480(9)° γ=90.00°
4-[(2-chlorobenzimidazol-1-yl)methyl]benzamide
(C15H12ClN3O)(H2O)
Crystal Growth & Design (2005) 5, 3 1283
a=6.0212(10)Å b=12.4652(19)Å c=19.166(3)Å
α=90.00° β=90.00° γ=90.00°
3-[(benzimidazol-1-yl)methyl]benzamide
C15H13N3O
Crystal Growth & Design (2005) 5, 3 1283
a=9.2133(11)Å b=11.6848(13)Å c=12.1071(15)Å
α=104.058(9)° β=98.623(8)° γ=94.900(7)°
3-[(2-chlorobenzimidazol-1-yl)methyl]-benzamide
C15H12ClN3O
Crystal Growth & Design (2005) 5, 3 1283
a=8.8067(7)Å b=11.8803(12)Å c=14.0856(15)Å
α=74.800(4)° β=72.485(5)° γ=68.786(4)°
3-[(benzimidazol-1-yl)methyl]benzamide, 4-nitrobenzoic acid
(C15H13N3O)(C7H5NO4)
Crystal Growth & Design (2005) 5, 3 1283
a=7.5178(9)Å b=9.1850(11)Å c=15.0850(15)Å
α=105.516(6)° β=100.600(7)° γ=100.339(8)°
3-[(2-methylbenzimidazol-1-yl)methyl]PhCOOH,(4-NO2PhCOOH)2
(C16H15N3O)(C7H5NO4)2
Crystal Growth & Design (2005) 5, 3 1283
a=7.5292(5)Å b=11.0980(8)Å c=17.2512(11)Å
α=81.865(4)° β=77.854(3)° γ=74.581(4)°
528 3-[(2-phenylimidazol-1-yl)methyl]benzamide, Cu2(2-FC6H4COO)4 (CH3CN)2
(C17H15N3O)2Cu2(C7H4O2F)4(C2H3N)4
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9819(16)Å b=11.2072(15)Å c=14.926(2)Å
α=99.042(8)° β=91.419(6)° γ=116.183(7)°